Focus:
While this acquisition exhibits a number of potential benefits, concerns have also been raised over the lack of commercial synergies between the two companies.
The axSpA market is anticipated to experience only mild growth in coming years. This is mainly due to the looming threat of biosimilars, despite the new treatments in development with...
AstraZeneca announced the success of its heart failure treatment Farxiga. This trial success could pave the way for a new treatment strategy in HF, helping to fulfil the multiple unmet...
GlobalData examines competition between prostate cancer therapies, amidst predictions of the market's expansion.
Minnesota-based CVRx has won FDA approval for the first neuromodulation device designed for the treatment of heart failure and high blood pressure.
Transcatheter aortic valve implantation (TAVI) is a relatively new procedure for the minimally invasive replacement of a patient’s aortic valve. In recent years, TAVI has exploded as an extremely successful...
Globally, millions of people suffer from trauma and burns as a result of accidents, natural disasters and violence. Mirroring global trends, wound therapies have steadily advanced to treat patients more...
Bariatric surgery - referring to medical procedures intended to result in weight loss - is a growing industry. The number of procedures is rising globally, with the market worth over...
Bayer announced on August 8 that it had entered an agreement to fully acquire BlueRock Therapeutics, a biotechnology company focused on cellular therapy development.
Knowing whether their blood glucose is rising or falling, and being able to follow patterns over time, is valuable information for people with diabetes, and would inform better treatment decisions.
